Replies to post #7 on Milestone Capital Growth Portfolio - Big Board Mov

[Wallstreetlive]

Keryx Pharmaceuticals (KERX) +12.4% premarket, enjoying a boost from two analyst buy recommendations. Ladenburg Thalmann notes data from the long-term Phase 3 study of hyposphatemia drug Zerenex (data expected in Q4) represents a "significant event" for KERX. Roth Capital raises its target price on the shares to $7 from $4.